Danaher Corporation thrives on bioprocessing demand and diagnostics resilience. Click for why, with solid execution and 80% ...

Q2 2025 Earnings Call Transcript July 22, 2025 Danaher Corporation beats earnings expectations. Reported EPS is $1.8, expectations were $1.64. Margaux: My name is Margaux, and I’ll be your conference ...

Montag A & Associates Inc. took a step back from Danaher, slashing their stake by a hefty 28.6%. The firm sold 8,037 shares, ...

Danaher Corp (DHR) reports robust free cash flow and bioprocessing growth, while navigating global trade tensions and Life ...

Danaher Corp (NYSE:DHR) on Tuesday reported second-quarter 2025 sales of $5.94 billion, up 3.5% year-over-year, beating the ...

Danaher (NYSE:DHR) reported its second-quarter 2025 results on July 22, 2025, with sales of $5.9 billion and core revenue growth of 1.5% year over year. Adjusted diluted EPS grew 5% to $1.80, free ...

Life sciences firm Danaher raised its annual profit forecast on Tuesday, banking on steady demand for bioprocessing from its pharmaceutical clients and a recovery in China.

Insights from Steven Cohen (Trades, Portfolio)'s First Quarter 2025 13F Filing. Warning! GuruFocus has detected 4 Warning ...

The firm's life sciences revenues rose 1 percent, while diagnostics revenues were up 2 percent and biotechnology revenues jumped 8 percent.

The Danaher Business System focuses on continuous improvement, including the acceleration of core growth and margin expansion through marketing initiatives and innovation, which appears positive for ...

Danaher (NYSE:DHR) stock falls even as the company beats Q2 2025 forecasts despite an underperformance at its Life Sciences ...

Danaher's second-quarter profit fell as expenses jumped, despite higher sales. The company also named Matthew Gugino as its next chief financial officer, effective from February 2026.